ARQ-255 is under clinical development by Arcutis Biotherapeutics and currently in Phase I for Alopecia Areata. According to GlobalData, Phase I drugs for Alopecia Areata does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ARQ-255 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ARQ-255 is under development for the treatment of alopecia areata. It is administered by topical route as suspension. The drug candidate is an alternate formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation. It acts by targeting JAK1 (Janus Kinase 1).
Arcutis Biotherapeutics overview
Arcutis Biotherapeutics (Arcutis), a subsidiary of Allspring Global Investments Holdings LLC, is a biopharmaceutical company. The company is in developing small molecules for the treatment of immune-mediated dermatological diseases and conditions. Its pipeline products includes a topical roflumilast cream, ARQ-252, a small molecule inhibitor of Janus kinase type 1 (JAK1) to treat rheumatoid arthritis, psoriasis, Crohn’s disease and atopic dermatitis and ARQ-255 for inflammation in alopecia areata. The company also investigating novel dermatology treatments in inflammation and immunology diseases. Arcutis is headquartered in Westlake Village, California, the US.
For a complete picture of ARQ-255’s drug-specific PTSR and LoA scores, buy the report here.